PTC Therapeutics, Inc. (PTCT) Institutional Ownership & Insider Trading

382 institutions reported holding PTC Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 235 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PTCTPTC Therapeutics, Inc.Follow PTCT — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 5.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

382 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +5.4%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	382	100	+5.4%	138	63	105	35
Mar 26	348	95	+3.5%	137	45	87	50
Dec 25	343	92	+11.0%	119	74	91	31
Sep 25	288	83	+3.6%	92	44	94	38
Jun 25	280	80	+1.7%	102	49	77	27
Mar 25	259	79	+1.4%	81	40	83	19
Dec 24	237	78	+2.3%	74	42	70	13
Sep 24	201	79	-3.7%	64	25	62	23

PTC Therapeutics, Inc. — questions

Who owns PTC Therapeutics, Inc. stock?: 382 institutions reported PTC Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (16.7%), RTW INVESTMENTS, LP (9.3%), Jupiter Topco LLC (8.7%).
Are PTC Therapeutics, Inc. insiders buying or selling?: 235 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from PTC Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.